上海凯宝 (300039)

Shanghai Kaibao Pharmaceutical Co.,Ltd.

ASZ

Tags

Venture Capital ConceptInvestments in Newly Listed CompaniesInfant and Child ConceptChiNext Small CapChiNext HealthcareShenzhen ConnectChinese Med. IIStable Growth IndexSZSE Medicine Equal Weight IndexSina 100 IndexShenzhen A-Share Pharmaceutical IndexCS High Dividend Yield IndexChiNext Composite IndexCSI All-share Pharmaceutical Sector IndexSZSE 700 IndexSSE 700 Growth IndexSZSE 1000 IndexCSI 1000 Growth IndexInfluenza/MaskNew Virus PreventionCOVID-19 PreventionNational Team Heavy HoldingsShanghai LocalYangtze River Delta Economic ZoneHuijin ConceptPrecision MedicineCNI 2000 IndexSME Board Innovation IndexEmerging Industries Composite IndexManufacturing IndexCS Pharmaceutical TI IndexCSI 1000 IndexChiNext Basic IndexPharmaceutical & Health 100 IndexCSI 1000 Growth Innovation IndexCSI 1000 Value IndexCSI 1000 Value Stable IndexShanghai

K-Line Chart

No K-line data available

Company NameShanghai Kaibao Pharmaceutical Co., Ltd.
Listing Date2010-01-08
Issue Price38RMB
Registered Capital10460010k RMB
Legal RepresentativeMu Jingwei
Registered AddressNo. 88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone
IndustryTraditional Chinese Medicine II
Main BusinessR&D, production, and sales of Tanreqing Injection, a traditional Chinese medicine for clearing heat and detoxifying.
Company ProfileShanghai Kaibao Pharmaceutical Co., Ltd. was established in 2000, primarily engaged in the R&D, production, and sales of modern traditional Chinese medicine. After 22 years of relentless effort, the company has received a series of honors. It is a national high-tech industrialization demonstration base for modern traditional Chinese medicine and one of China's Top 100 Pharmaceutical Enterprises. It was among the first traditional Chinese medicine injection enterprises to pass the new GMP (2010 version) certification. In recent years, it has consistently ranked among the top of the Top 100 Wealth List in Fengxian District, Shanghai, making significant contributions to the local economy. Since its listing ten years ago, the company has achieved a cumulative output value of nearly 12 billion yuan, paid cumulative taxes of 2.4 billion yuan, distributed cumulative dividends of 1.17 billion yuan, and issued 960 million bonus shares, delivering excellent results to society. It has released social responsibility reports for six consecutive years, actively fulfilling its social responsibilities. The company consistently adheres to the philosophy of 'making medicine with integrity and saving lives with good medicine' throughout every aspect of its production and operational activities. Currently, the company and its subsidiaries have gradually established three major product lines: the respiratory field represented by Tanreqing Injection, the cardiovascular and cerebrovascular field represented by Qishen Capsules, and the digestive field represented by Tiopronin series products, further enhancing the company's product competitiveness and brand influence.

Stock Details

1. Key Indicators

  • Total Shares(W): 104600.00
  • Circulating A-Shares(W): 91692.62
  • Earnings Per Share(RMB): 0.1788
  • Net Assets Per Share(RMB): 4.3451
  • Operating Revenue(W RMB): 81902.91
  • Total Profit(W RMB): 22036.39
  • Net Profit Attributable to Parent(W RMB): 18704.18
  • Net Profit Growth Rate(%): -13.83
  • Weighted Return on Equity(%): 10.7900
  • Operating Cash Flow Per Share(RMB): 0.1930
  • Undistributed Profit Per Share(RMB): 2.0949
  • Capital Reserve Per Share(RMB): 0.0082

2. Main Business

The main business covers:

  • Modern Traditional Chinese Medicine (TCM) R&D
  • Modern TCM Production
  • Modern TCM Sales

3. Company Basic Information

  • Company Name: Shanghai Kaibao Pharmaceutical Co., Ltd.
  • Listing Date: 2010-01-08
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone
  • Website: www.xykb.com
  • Company Profile：The company was established by the overall change of Shanghai Kaibao Pharmaceutical Co., Ltd. In August 2008, upon resolution of the shareholders' meeting, Shanghai Kaibao Pharmaceutical Co., Ltd. was transformed into Shanghai Kaibao Pharmaceutical Co., Ltd. and obtained the "Business License of Enterprise Legal Person" with registration number 310226000171574 issued by the Shanghai Administration for Industry and Commerce on September 8, 2008. The registered capital of the joint stock company was 82,200,000 yuan. Lixin Certified Public Accountants conducted the audit and capital verification for this overall change, issuing the Xinhui Shi Bao Zi (2008) No. 23625 "Audit Report" and Xinhui Shi Bao Zi (2008) No. 23656 "Capital Verification Report".

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Xinxiang Kaiyi Commerce and Trade Co., Ltd. General Legal Person 6850.40 7.47
2 Hong Kong Securities Clearing Company Ltd. Northbound Capital 699.22 0.76
3 Southern China Securities CSI 1000 ETF Fund 574.45 0.63
4 ChinaAMC CSI Traditional Chinese Medicine ETF Fund 390.98 0.43
5 China Universal CSI 1000 ETF Fund 341.02 0.37

5. Concept Sectors

  • Venture Capital Concept
  • Infant and Child Concept
  • Hepatitis Concept
  • Innovative Drug
  • Margin Trading & Securities Lending
  • Investing in New Shares
  • ChiNext Pharmaceutical
  • ChiNext Small Cap

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information